The US Food and Drug Administration (FDA) has approved Abbott’s new TactiCath Contact Force Ablation Catheter, Sensor Enabled, for the treatment of atrial fibrillation (AFib).
TactiCath has been developed to provide precise images of the heart along with real-time electrical activity information. Its design is said to enable superior reach and manoeuvrability during cardiac ablation.
Go deeper with GlobalData
The device is part of Abbott cardiac ablation portfolio based on the company’s EnSite Precision cardiac mapping system to deliver accurate heart images while performing ablation procedures.
TactiCath’s approval follows a recent FDA nod for Abbott’s Amplatzer Piccolo Occluder to treat patent ductus arteriosus (PDA) in premature babies and newborns.
Abbott Electrophysiology business medical director Srijoy Mahapatra said: “TactiCath SE directly supports our goal of supporting fast, effective and safe cardiac ablation procedures.
“As more physicians turn to cardiac ablation to treat AFib, Abbott’s goal is to equip them with the most advanced ablation catheters combined with the most advanced cardiac mapping on the market.”
Ablation catheters are commonly used to treat AFib by scarring tissue in the heart that generates abnormal electrical signals and disrupts a patient’s natural heartbeat.
To date, Abbott cardiac ablation technology has been used for the treatment of patients in more than 84 countries globally.
Physicians are currently evaluating the use of new tools such as ‘contact force’ technology to help them apply appropriate pressure during ablation procedures.
Abbott has also invested in technology to enhance the accuracy of cardiac mapping in order to support the procedures.
The company launched new clinical trials to gather clinical evidence associated with cardiac ablation, as well as introduced the Advisor HD Grid Mapping Catheter, Sensor Enabled, and the FlexAbility Ablation Catheter, Sensor Enabled.
